血小板成分在细菌筛选和病原体减少新进展时代的安全性：2024年ISBT输血传播传染病工作组细菌小组大会报告

IF 1.6 4区医学 Q3 HEMATOLOGY

Vox Sanguinis Pub Date : 2025-08-01 Epub Date: 2025-06-08 DOI:10.1111/vox.70053

Michel-Andrés García-Otálora, Carl McDonald, Jennifer Bearne, Bethany Brown, Anthea Cheng, Catherine Humbrecht, Pierre Tiberghien, Sandra Ramirez-Arcos

{"title":"血小板成分在细菌筛选和病原体减少新进展时代的安全性：2024年ISBT输血传播传染病工作组细菌小组大会报告","authors":"Michel-Andrés García-Otálora, Carl McDonald, Jennifer Bearne, Bethany Brown, Anthea Cheng, Catherine Humbrecht, Pierre Tiberghien, Sandra Ramirez-Arcos","doi":"10.1111/vox.70053","DOIUrl":null,"url":null,"abstract":"Background and objectives: High-income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.Materials and methods: Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion-Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.Results: PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.Conclusions: PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin-producing Staphylococcus aureus.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"846-857"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390369/pdf/","citationCount":"0","resultStr":"{\"title\":\"Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion-Transmitted Infectious Diseases Working Party, Bacteria Subgroup.\",\"authors\":\"Michel-Andrés García-Otálora, Carl McDonald, Jennifer Bearne, Bethany Brown, Anthea Cheng, Catherine Humbrecht, Pierre Tiberghien, Sandra Ramirez-Arcos\",\"doi\":\"10.1111/vox.70053\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and objectives: High-income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.Materials and methods: Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion-Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.Results: PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.Conclusions: PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin-producing Staphylococcus aureus.\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"846-857\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390369/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.70053\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70053","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景和目的：高收入国家通过实施缓解策略成功地提高了血小板成分（PC）的安全性，这些策略包括供体筛查、皮肤消毒、第一等分转移和血小板细菌筛查或使用病原体减少技术（PRT）进行治疗。这篇综述讨论了一些机构采用细菌筛选方法和/或PRT的经验，并强调了残留的安全风险。材料和方法：来自美国红十字会（ARC）、澳大利亚红十字会生命线（Lifeblood）、加拿大血液服务（CBS）、Établissement法国桑（EFS）和国家卫生服务血液和移植（NHSBT）的数据在国际输血学会（ISBT）大会、输血传播传染病会议（巴塞罗那，2024年6月）上发表，并在本报告中进行总结。结果：ARC和CBS于2004年开始使用自动BACT/ALERT培养系统进行PC筛查，Lifeblood和NHSBT分别于2008年和2011年采用该系统。PRT拦截的PC处理分别于2016年、2022年和2006年在ARC、CBS和EFS实施。结论：前列腺癌筛查及用PRT治疗前列腺癌可显著提高产品安全性。然而，仍有一些具有挑战性的生物，如芽孢杆菌和产毒金黄色葡萄球菌，带来了残留的安全风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion-Transmitted Infectious Diseases Working Party, Bacteria Subgroup.

查看原文本刊更多论文

Background and objectives: High-income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.

Materials and methods: Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion-Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.

Results: PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.

Conclusions: PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin-producing Staphylococcus aureus.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vox Sanguinis 医学-血液学

CiteScore

4.40

自引率

11.10%

发文量

156

审稿时长

6-12 weeks

期刊介绍： Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.